A Post-Authorization Safety Study (PASS) to Assess Long-term Safety in Patients with Pompe Disease Treated with Avalglucosidase alfa in the Real-World Setting: the SAVANT (Safety assessment of AValglucosidase Alfa as a Novel Treatment) studyFirst published 15/11/2023 Last updated 18/02/2025 EU PAS number: EUPAS107472StudyOngoing